Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of LuminoMark inj. Versus Charcotrace inj. for Nonpalpable Breast Lesions
KCT0006123Phase 3Completed
- Sponsor
- Hanlim Pharm
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indocyanine green + hyaluronic acid in breast lesion (2 arms), sponsored by Hanlim Pharm. Started Jun 2020; status: completed.
02
Drugs
indocyanine green + hyaluronic acid
03
Conditions
breast lesion
Beyond the preview
Go deeper on KCT0006123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006123.